Summary
Samenvatting medicatieveiligheidstoets
- Course
- Institution
Samenvatting van de reader van de medicatieveiligheidstoets. Tevens overal aanvullende (achtergrond)informatie en extra uitleg toegevoegd.
[Show more]
1 review
By: pietjanssen33 • 1 year ago
Seller
Follow
kkkayleigh07
Reviews received
Content preview
InhoudsopgaveA. Pijnmedicatie......................................................................................................................................3
PCM....................................................................................................................................................4
NSAIDs/Prostaglandinesynthetaseremmers.......................................................................................5
Opioïden.............................................................................................................................................7
Overview............................................................................................................................................9
B. Antistolling.......................................................................................................................................11
Tromboyctenaggregatieremmers.....................................................................................................13
Vitamine K-antagonisten/cumarinederivaten..................................................................................15
Heparines.........................................................................................................................................17
DOAC’s..............................................................................................................................................18
Overview..........................................................................................................................................19
C. Cardiovasculaire middelen...............................................................................................................21
Diuretica...........................................................................................................................................21
β-receptorblokkerende sympathicolytica.........................................................................................24
Calcium-antagonisten.......................................................................................................................26
RAS-Remmers...................................................................................................................................26
ACE remmers................................................................................................................................27
Angiotensine II – antagonisten.....................................................................................................29
Hartglycosiden (digoxine).................................................................................................................29
Nitraten............................................................................................................................................29
Overview..........................................................................................................................................30
D. Antidiabetica....................................................................................................................................32
Orale bloedglucose verlagende middelen........................................................................................33
Insuline.............................................................................................................................................35
Overview..........................................................................................................................................36
E. Antidepressiva..................................................................................................................................37
Antidepressiva..................................................................................................................................37
Lithium..............................................................................................................................................39
Overview..........................................................................................................................................39
F. Benzodiazepines...............................................................................................................................41
Overview..........................................................................................................................................42
G. Antibiotica........................................................................................................................................42
β-lactam-antibiotica.........................................................................................................................44
Tetracyclinen (doxycyline)................................................................................................................45
, Aminoglycosiden (gentamicine).......................................................................................................46
Macroliden (azitromycine)................................................................................................................46
Sulfonamiden/trimethoprim (co-trimoxazol)...................................................................................46
Chinolonen (ciprofloxacine)..............................................................................................................47
Middelen bij UWI (nitrofurantoïne, fosfomycine)............................................................................47
Midddelen bij anaerobe infecties (metronidazol)............................................................................48
Overview..........................................................................................................................................49
H. Farmacokinetiek...............................................................................................................................49
Absorptie..........................................................................................................................................49
Distributie.........................................................................................................................................50
Metabolisme.....................................................................................................................................50
Eliminatie..........................................................................................................................................50
Overview..........................................................................................................................................51
I. Geneesmiddelenallergie....................................................................................................................51
Anafylaxie (immunologisch/niet-immunologisch)............................................................................52
Trombocytopenie/hemolytische anemie..........................................................................................53
Ernstige huidreacties (severe cutaneous adverse reactions (SCAR))................................................54
Overview..........................................................................................................................................55
J. Wet- en regelgeving..........................................................................................................................55
K. Goed geneesmiddelengebruik..........................................................................................................56
L. Zwangerschap en lactatie.................................................................................................................58
Zwangerschap...................................................................................................................................58
Lactatie.............................................................................................................................................58
Te kennen geneesmiddelen..................................................................................................................59
,A. Pijnmedicatie
Analgetica
- Niet-opioïden PCM of Prostaglandinesynthetaseremmers
- Opioïden
Pathofysiologie van de pijn
Prostaglandines maken nociceptoren gevoeliger
Via vezels:
- C-vezels: gaan trager, geven doffe diepe pijn
- Aδ-vezels: gaan sneller, geven scherpe pijn
, WHO pijnladder
Fase 1 Paracetamol: 500 – 1000 mg 3-4 dd
Indien onvoldoende effect:
prostaglandinesynthethaseremmer
- Ibuprofen max 2400 mg in 4 – 6 doses
- Diclofenac 50 mg 2 – 4 dd
- Naproxen 250 – 500 mg 2 dd
Fase 2 Vervanging of toevoeging niet-opioïd fase 1 door/met zwak Deze stap wordt bij
werkend opioïd nociceptieve pijn bij kanker
- Codeïne 30 – 60 mg per keer, max 200 mg per dag meestal overgeslagen ivm
- Tramadol 50 – 100 mg 3 – 4 dd - Geringe pijn afname
(Codeïne en
tramadol)
- Bijwerkingen zoals
misselijkheid,
duizeligheid,
obstipatie (tramadol)
Fase 3 Onvoldoende werkzaamheid: Middel uit fase 3 wordt over
Sterker opioïd het algemeen gecombineerd
- Morfine retard 1 -2dd 10 – 30 mg met een middel uit fase 1
Max dosering bepaald door gewicht, leeftijd en vanwege de verschillende
eventueel optredende bijwerkingen aangrijpingspunten in het
- Fentanylpleister -> bij patiënten met stabiele pijnmechanisme
opioïdbehoefte en slikproblemen/braken
Nadeel fentanylpleister =
Opioïdrotatie: indien pijnstilling onvoldoende of bijwerkingen trage inwerkingtreding
onacceptabel kan van morfinepreparaat gewisseld worden
Fase 4 Indien andere toedieningswegen onvoldoende pijnstilling
geven: parentereale toediening
WHO pijnladder
PCM
Werking PCM
- Analgetisch
- Antipyretisch
- NIET anti-inflammatoir
Bijwerking: leverbeschadiging treedt op bij > 150 mg/kg per dag obv overbelasting metabole
verwerkingscapaciteit
Risicofactoren/risicogroepen:
Alcoholisme Max 2 g / dag
Pre-existent leverfalen
Slechte voedingstoestand
The benefits of buying summaries with Stuvia:
Guaranteed quality through customer reviews
Stuvia customers have reviewed more than 700,000 summaries. This how you know that you are buying the best documents.
Quick and easy check-out
You can quickly pay through credit card or Stuvia-credit for the summaries. There is no membership needed.
Focus on what matters
Your fellow students write the study notes themselves, which is why the documents are always reliable and up-to-date. This ensures you quickly get to the core!
Frequently asked questions
What do I get when I buy this document?
You get a PDF, available immediately after your purchase. The purchased document is accessible anytime, anywhere and indefinitely through your profile.
Satisfaction guarantee: how does it work?
Our satisfaction guarantee ensures that you always find a study document that suits you well. You fill out a form, and our customer service team takes care of the rest.
Who am I buying these notes from?
Stuvia is a marketplace, so you are not buying this document from us, but from seller kkkayleigh07. Stuvia facilitates payment to the seller.
Will I be stuck with a subscription?
No, you only buy these notes for $3.25. You're not tied to anything after your purchase.
Can Stuvia be trusted?
4.6 stars on Google & Trustpilot (+1000 reviews)
64438 documents were sold in the last 30 days
Founded in 2010, the go-to place to buy study notes for 14 years now